NAARDEN, The Netherlands and MIAMI, December 19, 2022 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company NV NAMESa clinical-stage company focused on the discovery and development of transformative oral therapies for severe cardiometabolic diseases, today announced the appointment of David Topper as Chief Financial Officer (“CFO”), effective January 1, 2023. Mr. Topper most recently served as Partner, Capital Markets at Frazier Healthcare Partners and as Chief Financial Officer and Board Director of Frazier Lifesciences Acquisition Corporation (“FLAC”), the Frazier-sponsored special purpose acquisition vehicle with which NewAmsterdam completed a business combination in November 2022 . He is succeeding Louise Kooij, who will transition to the role of Chief Accounting Officer (“CAO”).

“We are pleased to welcome David as our Chief Financial Officer,” said Michael Davidson, MD, Chief Executive Officer of NewAmsterdam. “The NewAmsterdam management team has worked extensively with David over the past few months to complete our merger, private placement and NASDAQ listing. His extensive experience in the capital markets and his strategic thinking will be of great benefit to NewAmsterdam as we continue to develop as a public society.”

dr Davidson continued, “We are very happy to have Louise take on the role of Chief Accounting Officer. Louise has been a key role in building the finance and business functions at NewAmsterdam. In her new role, Louise will continue to provide expert leadership to ensure we execute on our corporate strategy while maintaining a strong financial position.”

“Over the past few months, I have come to appreciate the NewAmsterdam team’s thoughtful and strategic approach to building the business and significant expertise in drug development, as well as obicetrapib’s potential to transform the care and treatment of serious cardiovascular disease.” said Mr. Topper. “I look forward to working with my new colleagues as we move forward…